A phase II study of palliative chemoradiation therapy with paclitaxel and cisplatin for local symptoms due to an unresectable primary advanced or locally recurrent gastric adenocarcinoma

A phase II study of palliative chemoradiation therapy with paclitaxel and cisplatin for local symptoms due to an unresectable primary advanced or locally recurrent gastric adenocarcinoma - chemoradiation therapy for advanced or recurrent gastric adenocarcinoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003201

Enrollment

Registered

2010-02-17

Start date

2009-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

chemoradiation therapy with paclitaxel and cisplatin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histologically confirmed gastric cancer 2) Patients who have local symptoms due to an unresectable primary advanced or locally recurrent gastric adenocarcinoma 3) Age between 20 to 80 at registration 4) ECOG PS 0 to 1 5) No or one history of chemotherapy for gastric cancer(adjuvant chemotherapy is excluded) 6) No history of chemotherapy with paclitaxel and cisplatin or chemotherapy including cisplatin(over 240mg/m2) 7) 3 weeks after other chemotherapy 8) No history of radiation therapy for left upper abdomen 9) Over 2 months survival is expected 10) adequate organ function 11) No other active malignancy 12) Written informed consent

Exclusion criteria

Exclusion criteria: 1) Tumor localization is not detected by neither CT, endoscopy nor upper GI series 2) Serious comorbidities 3) Severe GI obstruction or gastrointestinal bleeding 4) Current inflammation or acute inflammatory disease 5) Allergy to cremophor EL 6) Brain metastasis with symptom 7) Female with present pregnancy or breast-feeding, or contemplating pregnancy. 8) Registered to other clinical trial 9) Patients judged inappropriate for the study by the physicians

Design outcomes

Primary

Measure	Time frame
Improvement of gastrointestinal obstruction and/or localized pain	—

Secondary

Measure	Time frame
Improved duration of gastrointestinal obstruction , survival time, adverse event	—

Countries

Japan

Contacts

Public ContactTakanobu Yamada

Kanagawa Cancer Center Department of Gastrointesitnal Surgery

takay0218@yahoo.co.jp0455202222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026